These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 15303535

  • 21. [The effect of angiotensin II type 1 receptor blocker valsartan in rats with portal hypertensive gastropathy].
    Huo LJ, Huang HF, Yang BY.
    Zhonghua Gan Zang Bing Za Zhi; 2006 Aug; 14(8):611-3. PubMed ID: 16938177
    [No Abstract] [Full Text] [Related]

  • 22. Angiotensin-receptor-blocker-induced refractory hypotension responds to methylene blue.
    Nabbi R, Riess ML, Woehlck HJ.
    Acta Anaesthesiol Scand; 2012 Aug; 56(7):933-4. PubMed ID: 22571734
    [No Abstract] [Full Text] [Related]

  • 23. Terlipressin for catecholamine-resistant septic shock in children.
    Rodríguez-Núñez A, Fernández-Sanmartín M, Martinón-Torres F, González-Alonso N, Martinón-Sánchez JM.
    Intensive Care Med; 2004 Mar; 30(3):477-80. PubMed ID: 14767584
    [Abstract] [Full Text] [Related]

  • 24. JIKEI HEART Study--a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease.
    Mochizuki S, Shimizu M, Taniguchi I, Kanae K, Yoshida S, Tajima N, Dahlöf B, JIKEI HEART Study Group.
    Cardiovasc Drugs Ther; 2004 Jul; 18(4):305-9. PubMed ID: 15367828
    [Abstract] [Full Text] [Related]

  • 25. Terlipressin as rescue therapy for intractable hypotension during neonatal septic shock.
    Matok I, Leibovitch L, Vardi A, Adam M, Rubinshtein M, Barzilay Z, Paret G.
    Pediatr Crit Care Med; 2004 Mar; 5(2):116-8. PubMed ID: 14987339
    [Abstract] [Full Text] [Related]

  • 26. Renal and metabolic effects of valsartan.
    Ecder T.
    Anadolu Kardiyol Derg; 2014 Dec; 14 Suppl 2():S14-9. PubMed ID: 25604203
    [Abstract] [Full Text] [Related]

  • 27. Hypertension and valsartan.
    Kızılırmak P, Üresin AY.
    Anadolu Kardiyol Derg; 2014 Dec; 14 Suppl 2():S20-4. PubMed ID: 25604204
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
    Andrés A, Morales E, Morales JM, Bosch I, Campo C, Ruilope LM, Valsartan in Renal Transplantation Group.
    Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
    [Abstract] [Full Text] [Related]

  • 29. Catecholamine-resistant hypotension following induction for spinal exploration.
    Trotter J.
    AANA J; 2012 Feb; 80(1):55-60. PubMed ID: 22474806
    [Abstract] [Full Text] [Related]

  • 30. Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients.
    Yang HY, Kao PF, Chen TH, Tomlinson B, Ko WC, Chan P.
    J Clin Pharmacol; 2007 Mar; 47(3):397-403. PubMed ID: 17322151
    [Abstract] [Full Text] [Related]

  • 31. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 32. Upregulation of angiotensin II type 2 receptor and limitation of myocardial stunning by angiotensin II type 1 receptor blockers during reperfused myocardial infarction in the rat.
    Jugdutt BI, Menon V.
    J Cardiovasc Pharmacol Ther; 2003 Sep 20; 8(3):217-26. PubMed ID: 14506547
    [Abstract] [Full Text] [Related]

  • 33. Should the angiotensin II antagonists be discontinued before surgery?
    Bertrand M, Godet G, Meersschaert K, Brun L, Salcedo E, Coriat P.
    Anesth Analg; 2001 Jan 20; 92(1):26-30. PubMed ID: 11133595
    [Abstract] [Full Text] [Related]

  • 34. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
    White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S.
    Hypertension; 2011 Mar 20; 57(3):413-20. PubMed ID: 21282560
    [Abstract] [Full Text] [Related]

  • 35. Valsartan in chronic heart failure.
    Ripley TL.
    Ann Pharmacother; 2005 Mar 20; 39(3):460-9. PubMed ID: 15687480
    [Abstract] [Full Text] [Related]

  • 36. The Valsartan Antihypertensive Long-Term Use Evaluation trial: a study in contrasts.
    Sica DA.
    Hypertension; 2006 Sep 20; 48(3):362-3. PubMed ID: 16864742
    [No Abstract] [Full Text] [Related]

  • 37. New basic science initiatives with the angiotensin II receptor blocker valsartan.
    de Gasparo M.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun 20; 1(2 Suppl):S3-5. PubMed ID: 17199210
    [Abstract] [Full Text] [Related]

  • 38. Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.
    Disertori M, Latini R, Maggioni AP, Delise P, Di Pasquale G, Franzosi MG, Staszewsky L, Tognoni G, GISSI-AF Investigators.
    J Cardiovasc Med (Hagerstown); 2006 Jan 20; 7(1):29-38. PubMed ID: 16645357
    [Abstract] [Full Text] [Related]

  • 39. Renin-angiotensin system blockade in the treatment of heart failure and the role of valsartan in this treatment.
    Kılıçkıran Avcı B, İkitimur B, Karadağ B, Öngen Z.
    Anadolu Kardiyol Derg; 2014 Dec 20; 14 Suppl 2():S1-8. PubMed ID: 25604202
    [Abstract] [Full Text] [Related]

  • 40. The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension.
    Saiki A, Ohira M, Endo K, Koide N, Oyama T, Murano T, Miyashita Y, Shirai K.
    Diabetes Res Clin Pract; 2006 Dec 20; 74(3):242-8. PubMed ID: 16713009
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.